<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832884</url>
  </required_header>
  <id_info>
    <org_study_id>00570-FB</org_study_id>
    <nct_id>NCT00832884</nct_id>
    <nct_alias>NCT00720863</nct_alias>
  </id_info>
  <brief_title>The Safety of Intravenous Lacosamide</brief_title>
  <official_title>IV Lacosamide: The Safety of Intravenous Lacosamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Le Bonheur Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Le Bonheur Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of IV Lacosamide in children with partial-onset epilepsy, ages 4-35
      years old, inclusive, who are either unable to take oral medication or require intravenous
      administration of IV Lacosamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lacosamide tablets and intravenous formulations were both approved in the United States in
      the fall of 2008. Lacosamide is indicated for use as adjunctive therapy in the treatment of
      partial onset seizure disorder in patients' age seventeen years and older. A parenteral
      dosage form of Lacosamide is desirable for patients who are temporarily unable to take
      medication orally. The objective of this study is to evaluate the safety of IV Lacosamide in
      children with epilepsy, ages 4 to 35 years, who are either unable to take oral medication, or
      whom parenteral administration of IV Lacosamide is desirable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of IV Lacosamide given as a rapid infusion.</measure>
    <time_frame>one year</time_frame>
    <description>The safety of IV Lacosamide will be assessed in patients in whom parental administration of Lacosamide is warranted.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 50 mg, once, 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 100 mg, once, 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 150 mg, once, 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 200 mg, once, 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 50 mg, once, 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 100 mg, once, 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 150 mg, once, 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 200 mg, once, 15 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes</description>
    <arm_group_label>Group 1A</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes</description>
    <arm_group_label>Group 2A</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes</description>
    <arm_group_label>Group 3A</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes</description>
    <arm_group_label>Group 4A</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes</description>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes</description>
    <arm_group_label>Group 2B</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes</description>
    <arm_group_label>Group 3B</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes</description>
    <arm_group_label>Group 4B</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of epilepsy and have received anti-epileptic drug
             therapy prior to initiation of IV Lacosamide

          -  Patients must have a medical condition in which the parenteral administration of
             Lacosamide is desirable.

          -  Patients may be male or female.

          -  Patients must be 4 years of age or older, and less than age 35 years.

          -  Patient or his / her legally authorized representative must sign an informed consent
             form prior to any study specific procedures.

        Exclusion Criteria:

          -  Patients will be excluded from entry into the study if any of the following are true:

          -  Patient has previously participated in any other intravenous Lacosamide study.

          -  Patient has status epilepticus within the last 3 months.

          -  Patient has a history of drug allergy to Lacosamide.

          -  Patient is pregnant.

          -  Patient has taken experimental drug within last 30 days.

          -  Patient with significant hepatic or renal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Wheless, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LeBonheur Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LeBonheur Children's Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lebonheur.org</url>
    <description>Study site website</description>
  </link>
  <results_reference>
    <citation>Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008 Mar;49(3):418-24. Epub 2007 Sep 19.</citation>
    <PMID>17888078</PMID>
  </results_reference>
  <results_reference>
    <citation>Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001 Jan;43(1):11-58.</citation>
    <PMID>11137386</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Le Bonheur Children's Hospital</investigator_affiliation>
    <investigator_full_name>James W. Wheless</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>partial</keyword>
  <keyword>onset</keyword>
  <keyword>epilepsy</keyword>
  <keyword>pediatric</keyword>
  <keyword>lacosamide</keyword>
  <keyword>partial onset epilepsy</keyword>
  <keyword>vimpat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

